Cerus Corporation Secures Regulatory Approvals for INT200 Device in France and Switzerland

Reuters
28 May
<a href="https://laohu8.com/S/CERS">Cerus Corporation</a> Secures Regulatory Approvals for INT200 Device in France and Switzerland

Cerus Corporation has announced that its next-generation INT200 illumination device has received regulatory approvals from France and Switzerland. The French National Agency for Medicines and Health Product Safety (ANSM) and the Swiss Agency for Therapeutic Products (Swissmedic) have both approved the INT200 for use with the INTERCEPT Blood System for Platelets and Plasma. These approvals are seen as a significant validation of Cerus' technology. The company has begun the commercial rollout of the INT200 and plans to transition its existing INT100 installations in the EMEA region to the INT200 over the next three years. The INT200, featuring a new vertical configuration and enhanced software, aims to improve workflow and ergonomics in blood center operations. Further regulatory submissions are planned, including a PMA submission to the FDA in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cerus Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250528251885) on May 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10